论文部分内容阅读
目的:探讨半枝莲乙醇提取物(ESB)对顺铂抗肝癌的增效作用。方法:3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium(MTS)/phenazine methosulfate(PMS)法检测ESB与顺铂单独及联合用药对肝癌细胞增殖的影响,金正均法计算Q值判断两药相互作用关系;建立肝癌H22实体瘤荷瘤小鼠模型,检测ESB与顺铂单独及联合用药对小鼠移植瘤的抑瘤率。结果:ESB与顺铂单独用药可呈时间和浓度依赖性的抑制肝癌细胞的增殖;ESB与低剂量顺铂联合应用后对两种肝癌细胞的抑制作用要大于单独应用的抑制率(P<0.05,P<0.01),且可产生协同抗肝癌作用(Q>1.15)。体内实验结果表明,低剂量顺铂+ESB组可产生与顺铂对照组相似的抑瘤作用,肿瘤重量均明显小于模型组(P<0.05),抑瘤率分别为53.44%和65.39%。结论:ESB与低剂量顺铂联合应用时,体外可显著增强顺铂对肝癌细胞增殖的抑制作用;体内能显著提高顺铂对小鼠H22肝癌移植瘤的抑瘤效果。
Objective: To investigate the synergistic effect of Scutellaria barbata ethanol extract (ESB) against cisplatin against liver cancer. Methods: The inhibitory effect of ESB combined with cisplatin (3-carboxymethoxyphenyl) -2- (4-sulfophenyl) -2H-tetrazolium (MTS) / phenazine methosulfate (PMS) Alone and in combination on the proliferation of hepatocellular carcinoma cells, the mean value of the method is used to calculate the Q value to determine the relationship between the two drugs; established H22 solid tumor tumor-bearing mouse model of liver cancer, ESB and cisplatin alone and in combination on the transplanted tumor Inhibition rate. Results: ESB combined with cisplatin alone could inhibit the proliferation of hepatocellular carcinoma cells in a time and concentration dependent manner. The inhibitory effect of ESB and cisplatin combined with low dose of cisplatin on the two hepatocellular carcinoma cells was greater than that of single administration (P <0.05 , P <0.01), and can produce synergistic anti-liver cancer effect (Q> 1.15). The results of in vivo experiments showed that low dose cisplatin + ESB group had similar antitumor activity to cisplatin control group, and tumor weight was significantly lower than that of model group (P <0.05). The tumor inhibition rates were 53.44% and 65.39% respectively. Conclusion: ESB combined with low-dose cisplatin can significantly enhance the inhibitory effect of cisplatin on the proliferation of hepatocellular carcinoma cells in vitro, and can significantly enhance the anti-tumor effect of cisplatin on H22 hepatoma transplanted tumor in vivo.